AIM Vaccine Gets US FDA Clinical Trial Nod for Respiratory Syncytial Virus Jab

MT Newswires Live

2025/02/27

The US Food and Drug Administration approved AIM Vaccine's (HKG:6660) clinical trial for its mRNA respiratory syncytial virus vaccine, according to a Wednesday filing with the Hong Kong exchange.

Animal tests showed the drug's virus-neutralizing potency and T-cell immunity were higher than those of its peers, the filing said.

Respiratory syncytial virus causes deaths in infants under one year old and also affects elderly patients, according to the company.

Price (HKD): $5.98, Change: $+0.37, Percent Change: +6.60%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514118248"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514118248\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514118248?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514118248","market":"sg","top_or_hot":-1,"title":"AIM Vaccine Gets US FDA Clinical Trial Nod for Respiratory Syncytial Virus Jab","media":"MT Newswires Live","content":"<html><body><p> The US Food and Drug Administration approved AIM Vaccine's (HKG:6660) clinical trial for its mRNA respiratory syncytial virus vaccine, according to a Wednesday filing with the Hong Kong exchange.</p><p>Animal tests showed the drug's virus-neutralizing potency and T-cell immunity were higher than those of its peers, the filing said.</p><p>Respiratory syncytial virus causes deaths in infants under one year old and also affects elderly patients, according to the company.</p><p>Price (HKD): $5.98, Change: $+0.37, Percent Change: +6.60%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIM Vaccine Gets US FDA Clinical Trial Nod for Respiratory Syncytial Virus Jab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIM Vaccine Gets US FDA Clinical Trial Nod for Respiratory Syncytial Virus Jab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-27 10:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The US Food and Drug Administration approved AIM Vaccine's (HKG:6660) clinical trial for its mRNA respiratory syncytial virus vaccine, according to a Wednesday filing with the Hong Kong exchange.</p><p>Animal tests showed the drug's virus-neutralizing potency and T-cell immunity were higher than those of its peers, the filing said.</p><p>Respiratory syncytial virus causes deaths in infants under one year old and also affects elderly patients, according to the company.</p><p>Price (HKD): $5.98, Change: $+0.37, Percent Change: +6.60%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIM","symbol_name":"AIM ImmunoTech Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514118248","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514118248","pubTimestamp":1740622156,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The US Food and Drug Administration approved AIM Vaccine's  clinical trial for its mRNA respiratory syncytial virus vaccine, according to a Wednesday filing with the Hong Kong exchange.Animal tests showed the drug's virus-neutralizing potency and T-cell immunity were higher than those of its peers, the filing said.Respiratory syncytial virus causes deaths in infants under one year old and also affects elderly patients, according to the company.Price : $5.98, Change: $+0.37, Percent Change: +6.60%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIM":"AIM ImmunoTech Inc.","06660":"艾美疫苗","BK4526":"热门中概股","BK4588":"碎股","HKD":"尚乘数科","BK4023":"应用软件","BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK4557":"大麻股","BK4139":"生物科技"},"translate_title":"AIM疫苗获得美国FDA批准呼吸道合胞病毒疫苗临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIM":1,"06660":0.9,"HKD":1},"content_text":"The US Food and Drug Administration approved AIM Vaccine's (HKG:6660) clinical trial for its mRNA respiratory syncytial virus vaccine, according to a Wednesday filing with the Hong Kong exchange.Animal tests showed the drug's virus-neutralizing potency and T-cell immunity were higher than those of its peers, the filing said.Respiratory syncytial virus causes deaths in infants under one year old and also affects elderly patients, according to the company.Price (HKD): $5.98, Change: $+0.37, Percent Change: +6.60%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}